broadest_icon

Broadest pegfilgrastim
biosimilar
coverage*

icon_preferred

~70% parity or preferred
commercial coverage

icon_cross

~70% parity or preferred
Medicare Advantage coverage

UDENYCA has favorable benefit coverage
with major plans:

  • Blue Shield of California
  • Cigna Commercial and Medicare Advantage
  • UnitedHealthcare Commercial and Medicare Advantage

UDENYCA autoinjector has broad pharmacy
benefit coverage with major plans:

  • Anthem Commercial
  • Humana Medicare Advantage
  • UnitedHealthcare Commercial

Please reach out to your Accord BioPharma Reimbursement Manager with any questions. All presentations of UDENYCA may be covered under patient’s medical benefit, and the autoinjector and prefilled syringe may be covered under both pharmacy and medical benefits.

*For all insurance types inclusive of commercial and Medicare as of June 2026.
Other Blue Cross Blue Shield plans have moved UDENYCA from nonpreferred to advantaged.

Check state-by-state coverage with the Payer Coverage Tool

CHECK COVERAGE

accord-care_logo

AccordCares® provides patient support services designed to
help remove hurdles to access UDENYCA

copay
copay

AccordCares offers a co-pay program for eligible patients with commercial
insurance that covers out-of-pocket expenses related to UDENYCA.

  • Eligible patients may pay as little as $0 co-pay per UDENYCA treatment
  • Annual maximum benefit of $15,000 for out-of-pocket expenses for
    UDENYCA, including co-pays or co-insurance. $4,500 per claim and per unit
    (or per 6 mg/0.6 mL dose), up to 2 units for $9,000

Other Offerings from AccordCares:

icon_benefits

Benefits investigation

icon_prior

Prior authorization support and information

icon_billing

Billing and coding information

icon_alternative

Alternate funding referral

An AccordCares associate can be reached
Monday through Friday, 8 AM to 8 PM ET, at:

Phone 1-844-483-3692
Fax 1-877-226-6370
Mail PO Box 7613, Overland Park, KS 66207

Enroll today in the AccordCares
Co-Pay Savings Program

GET STARTED

CO-PAY SAVINGS SUPPORT PROGRAM TERMS AND CONDITIONS

To receive co-pay assistance for drug or administration co-pay costs, the provider, patient, or caregiver must enroll the eligible individual within 180 days after the date of service for which the subsidy is sought.

Participating patients, pharmacies, physician offices, and hospitals may use Accord’s patient services web portal or fax completed enrollment forms to 1-877-226-6370 to enroll patients.

Under the Co-Pay Savings Program, if a patient incurs a co-pay obligation for the cost of UDENYCA and meets all eligibility requirements, Accord may provide co-pay assistance for up to $15,000 per calendar year. The Co-Pay Savings Program only covers the cost of the drug. It does not cover costs associated with drug administration.

The program benefits will reset every January 1st. Re-enrollment in the program is required at regular intervals. Patients may participate in the program as long as the patient re-enrolls as required by Accord BioPharma and continues to meet all of the eligibility requirements for the program during participation in the program. After reaching the maximum benefit for either program, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the program’s benefits cannot exceed the patient’s out-of-pocket expenses for the cost of UDENYCA.

Patients must have commercial health insurance. Patients with any federal, state, or government-funded healthcare coverage such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or Tricare are not eligible for the program.

The documentation required for claim submission, which can include but is not limited to an Explanation of Benefits (EOB) and claim form (e.g., CMS 1500), must be submitted within 365 days of the date that the primary claim was processed by the patient’s insurance to receive the co-pay savings benefit. Exceptions will not be made for claims submitted more than 365 days.

This Co-Pay Savings Program is offered to and intended for the sole benefit of eligible patients and may not be utilized for the benefit of third parties, including, without limitation, third-party payers, pharmacy benefit managers, or the agents of either. The program is not available if the costs are eligible to be reimbursed in their entirety by private insurance plans or other programs. The program is not available for patients receiving assistance from any other third party, including charitable organizations, if assistance is for the same expenses covered by the program.

This program is not health insurance or a benefit plan. Patient and provider agree to not seek reimbursement for any or all of the benefit received by the patient through the Co-Pay Savings Program. Patient and provider are responsible for reporting receipt of Co-Pay Savings Program benefits to any insurer, health plan, or other third party who pays for or reimburses any part of the drug cost, as may be required.

All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. The program is only valid in the United States and otherwise void where prohibited by law. Program benefits may not be sold, purchased, traded, or offered for sale. The program does not obligate use of any specific product or provider. Healthcare providers may not advertise or otherwise use the programs as a means of promoting their services or Accord products to patients. Accord reserves the right to rescind, revoke, or amend the program without notice at any time.

Access helpful videos
and materials

GET RESOURCES

helpfull-vids
Show more Show more Show more

IMPORTANT SAFETY INFORMATION

UDENYCA (pegfilgrastim-cbqv) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis.

Splenic rupture: Splenic rupture, including fatal cases, can occur following administration of pegfilgrastim products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.

IMPORTANT SAFETY INFORMATION

UDENYCA (pegfilgrastim-cbqv) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis.

Splenic rupture: Splenic rupture, including fatal cases, can occur following administration of pegfilgrastim products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.

Show less Show less Show less

IMPORTANT SAFETY INFORMATION

UDENYCA (pegfilgrastim-cbqv) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis.

Splenic rupture: Splenic rupture, including fatal cases, can occur following administration of pegfilgrastim products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.

Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA in patients with ARDS.

Serious allergic reactions, including anaphylaxis: The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue UDENYCA in patients with serious allergic reactions.

Allergies to acrylics (UDENYCA ONBODY® only): The on-body injector (OBI) for UDENYCA uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in a significant reaction.

Sickle cell disorders: Severe and sometimes fatal crises have occurred in patients with sickle cell disorders. Discontinue UDENYCA if sickle cell crisis occurs.

Glomerulonephritis: The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events resolved after dose reduction or discontinuation. Evaluate and consider dose-reduction or interruption of UDENYCA if causality is likely.

Leukocytosis: White blood cell (WBC) counts of 100 x 10⁹/L or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count during UDENYCA therapy is recommended.

Thrombocytopenia: Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts.

Capillary leak syndrome: Has been reported after granulocyte colony stimulating factor (G-CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency and severity and may be life-threatening if treatment is delayed. If symptoms develop, closely monitor and give standard symptomatic treatment, which may include a need for intensive care.

Potential for tumor growth stimulatory effects on malignant cells: The G-CSF receptor through which pegfilgrastim products and filgrastim products act has been found on tumor cell lines. The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast or lung cancer: MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast or lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

Potential device failures (UDENYCA ONBODY® only): Missed or partial doses have been reported in patients receiving UDENYCA via the OBI due to the device not performing as intended. In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered. Instruct patients using the OBI to notify their healthcare professional immediately to determine the need for a replacement dose of UDENYCA if they suspect that the device may not have performed as intended.

Aortitis: Has been reported in patients receiving pegfilgrastim products, occurring as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and WBC count). Consider aortitis when signs and symptoms develop without known etiology. Discontinue UDENYCA if aortitis is suspected.

Nuclear imaging: Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. Consider when interpreting bone imaging results.

The most common adverse reactions (≥5% difference in incidence compared to placebo) are bone pain and pain in extremity.

INDICATION

UDENYCA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitation of Use
UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

To report SUSPECTED ADVERSE REACTIONS, contact Accord BioPharma Inc at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

UDENYCA® is supplied as:

  • Prefilled syringe: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only
  • Autoinjector: 6 mg/0.6 mL in a single-dose prefilled autoinjector
  • UDENYCA ONBODY®: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector for UDENYCA®

For more information, please see the full Prescribing Information.

Reference: 1. Data on file. Accord BioPharma, Inc.; 2025.